Fungal Eye Infection Market Research Report – Global Forecast till 2027

Fungal eye infection market information: diagnosis (CT scan, MR scan, chromosome analysis, ultrasonography) treatment (antifungal medication, eye surgery) end-users (hospitals & clinics, research centers, specialty eye clinics) – Global forecast till 2027

ID: MRFR/Pharma/4052-HCR | February 2021 | Region: Global | 550 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario:


Fungal eye infections are rare, but they can be very serious. Fungal eye infection is a result of an eye injury. Inflammation or infection in the interior of the eye is called endophthalmitis and inflammation/infection of the cornea is known as keratitis.


Fungal eye infections are caused by a number of infectious species such as candida, aspergillus, cryptococcus, histoplasma, pneumocystis, and stachybotrys. There are approximately 1.5 million different species of fungi on the earth. However, only around 300 are responsible for causing diseases and infections in humans.


According to a survey carried out by Cidara Therapeutics, Inc. in 2015, approximately 97,000 deaths are associated annually in the U.S. with fungal infections. Changing lifestyle and increasing pollution has increased the possibilities of the fungal infections.


 The global fungal eye infections market is majorly driven by increasing prevalence of fungal infection, continuously increasing geriatric population and increasing number of patients suffering from a various fungal infection. However, the growth of the market is restricted due to side-effects of the treatment. For instance, in contrast to the remedial effects, antifungal treatment can have many side effects as well. Some of them include irritation, itching, headache, diarrhea, and anemia. In some cases, they are also responsible for causing kidney and liver damage.


The global fungal eye infection market is expected to grow at a CAGR of 5.3% during the forecasted period.


Figure: Global Fungal Eye Infection Market, by Region, 2016 (%)


 Fungal Eye Infection


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, market research future analysis, annual report, white paper, company presentation


Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


 Research Methodology:


 Fungal Eye Infection 2


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, market research future analysis, annual report, white paper, company presentation


Segments  


The global fungal eye infection market is segmented on the basis of diagnosis, treatment, and end-users.


On the basis of the diagnosis, the market is segmented into CT scan, MR scan, chromosome analysis, ultrasonography, and others.


Based on the treatment, the market is segmented into antifungal medication, eye surgery, and others.


On the basis of the end-users, the market is segmented into hospitals & clinics, research centers, specialty eye clinics, and others.


Regional Analysis


The Americas account for the largest share in the global fungal eye infection market owing to the presence of key players in the market and rising emphasis on diagnosis and treatment of rare diseases. Furthermore, the rising awareness about fungal eye infection further accelerates the growth of the market. North America is the accounted for the highest market share in this region with the U.S. being the largest market followed by Canada.


Europe is the second largest market and holds a noticeable share in the global fungal eye infection market. The European market is expected to grow significantly during the forecast period owing to the availability of advanced treatment facilities, skilled medical professionals. Furthermore, extensive research and development activities for the treatment of rare disease and increasing government support boost the market growth.  


Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases such as diabetes, cancer and fungal eye infection in developing countries is the major driver for the market growth. India is the fastest growing region owing to an increasing geriatric population. Also, the fungal eye infection is one of the major chronic conditions affecting a large number of patients, thereby influencing the market growth. Rising awareness about the infections and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of healthcare diagnostic and treatment industry also drive the market.


The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness about the fungal eye infection, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers.


Key Players       


Some of the key players in fu market are Allergan Inc., Abbott, Merck & Co., Inc., Bayer AG, Astellas Pharma, Inc., GlaxoSmithKline plc, Sigma-Aldrich, Novartis AG, Pfizer, Inc., Enzon Pharmaceuticals, Alcon Laboratories Inc., Johnson & Johnson Ltd. and others.



Frequently Asked Questions (FAQ) :


Fungal eye infection market is projected to grow at approximately 5.3% CAGR during the assessment period (2020-2027).

Side-effects of the treatment in contrast to the remedial effects, such as irritation, itching, headache, diarrhea, and anemia are the major tailwinds pushing the growth of the global fungal eye infection market.

High procedural cost and complications such as deep vein thrombosis, need for repeated surgery, and stiffness in the joints of the toes are major growth impeders for the global fungal eye infection market.

North America holds the largest share in the global fungal eye infection market, followed by Europe and the Asia Pacific, respectively.

Abbott, Allergan Inc., Merck & Co., Inc., Astellas Pharma, Inc., Bayer AG, GlaxoSmithKline plc, Novartis AG, Sigma-Aldrich, Pfizer, Inc., Alcon Laboratories Inc., Enzon Pharmaceuticals, and Johnson & Johnson Ltd., are some of the top players operating in the global fungal eye infection market.

Table of Content


1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Fungal Eye Infection Market, by Diagnosis

6.1 Introduction

6.2 CT scan

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 MR scan

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 Chromosome analysis

6.4.1 Market Estimates & Forecast, 2020-2027

6.5 Ultrasonography

6.4.1 Market Estimates & Forecast, 2020-2027

7. Global Fungal Eye Infection Market, by Treatment

7.1 Introduction

7.2 Eye Surgery

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Others

7.3.1 Market Estimates & Forecast, 2020-2027

8. Global Fungal Eye Infection Market, by End User

8.1 Introduction

8.2 Hospitals & Clinics

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Research centers

8.3.1 Market Estimates & Forecast, 2020-2027

9. Global Fungal Eye Infection Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 U.K.

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 Allergan Inc

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Abbott

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Merck & Co., Inc

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Bayer AG

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Astellas Pharma, Inc

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 GlaxoSmithKline plc

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Pfizer, Inc

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical Industry

14 Appendix

LIST OF TABLES

Table 1 Fungal Eye Infection Industry Synopsis, 2020-2027

Table 2 Global Fungal Eye Infection Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Global Fungal Eye Infection Market by Region, 2020-2027, (USD Million)

Table 4 Global Fungal Eye Infection Market by Diagnosis, 2020-2027, (USD Million)

Table 5 Global Fungal Eye Infection Market by Treatment, 2020-2027, (USD Million)

Table 6 Global Fungal Eye Infection Market by End Users, 2020-2027, (USD Million)

Table 7 North America Fungal Eye Infection Market by Diagnosis, 2020-2027, (USD Million)

Table 8 North America Fungal Eye Infection Market by Treatment, 2020-2027, (USD Million)

Table 9 North America Fungal Eye Infection Market by End Users, 2020-2027, (USD Million)

Table 10 U.S. Fungal Eye Infection Market by Diagnosis, 2020-2027, (USD Million)

Table 11 US Fungal Eye Infection Market by Treatment, 2020-2027, (USD Million)

Table 12 US Fungal Eye Infection Market by End Users, 2020-2027, (USD Million)

Table 13 Canada Fungal Eye Infection Market by Diagnosis, 2020-2027, (USD Million)

Table 14 Canada Fungal Eye Infection Market by Treatment, 2020-2027, (USD Million)

Table 15 Canada Fungal Eye Infection Market by End Users, 2020-2027, (USD Million)

Table 16 South America Fungal Eye Infection Market by Diagnosis, 2020-2027, (USD Million)

Table 17 South America Fungal Eye Infection Market by Treatment, 2020-2027, (USD Million)

Table 18 South America Fungal Eye Infection Market by End Users, 2020-2027, (USD Million)

Table 19 Europe Fungal Eye Infection Market by Diagnosis, 2020-2027, (USD Million)

Table 20 Europe Fungal Eye Infection Market by Treatment, 2020-2027, (USD Million)

Table 21 Europe Fungal Eye Infection Market by End Users, 2020-2027, (USD Million)

Table 22 Western Europe Fungal Eye Infection Market by Diagnosis, 2020-2027, (USD Million)

Table 23 Western Europe Fungal Eye Infection Market by Treatment, 2020-2027, (USD Million)

Table 24 Western Europe Fungal Eye Infection Market by End Users, 2020-2027, (USD Million)

Table 25 Eastern Europe Fungal Eye Infection Market by Diagnosis, 2020-2027, (USD Million)

Table 26 Eastern Europe Fungal Eye Infection Market by Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe Fungal Eye Infection Market by End Users, 2020-2027, (USD Million)

Table 28 Asia Pacific Fungal Eye Infection Market by Diagnosis, 2020-2027, (USD Million)

Table 29 Asia Pacific Fungal Eye Infection Market by Treatment, 2020-2027, (USD Million)

Table 30 Asia Pacific Fungal Eye Infection Market by End Users, 2020-2027, (USD Million)

Table 31 Middle East & Africa Fungal Eye Infection Market by Diagnosis, 2020-2027, (USD Million)

Table 32 Middle East & Africa Fungal Eye Infection Market by Treatment, 2020-2027, (USD Million)

Table 33 Middle East & Africa Fungal Eye Infection Market by End Users, 2020-2027, (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Fungal Eye Infection Market

Figure 3 Segmentation Market Dynamics for Fungal Eye Infection Market

Figure 4 Global Fungal Eye Infection Market Share, by Diagnosis 2020

Figure 5 Global Fungal Eye Infection Market Share, by Treatment 2020

Figure 6 Global Fungal Eye Infection Market Share, by End Users, 2020

Figure 7 Global Fungal Eye Infection Market Share, by Region, 2020

Figure 8 North America Fungal Eye Infection Market Share, by Country, 2020

Figure 9 Europe Fungal Eye Infection Market Share, by Country, 2020

Figure 10 Asia Pacific Fungal Eye Infection Market Share, by Country, 2020

Figure 11 Middle East & Africa Fungal Eye Infection Market Share, by Country, 2020

Figure 12 Global Fungal Eye Infection Market: Company Share Analysis, 2020 (%)

Figure 13 Merck & Co., Inc: Key Financials

Figure 14 Merck & Co., Inc: Segmental Revenue

Figure 16 Merck & Co., Inc: Geographical Revenue

Figure 17 Abbott: Key Financials

Figure 18 Abbott: Segmental Revenue

Figure 19 Abbott: Geographical Revenue

Figure 20 Pfizer Inc: Key Financials

Figure 21 Pfizer Inc: Segmental Revenue

Figure 22 Pfizer Inc: Geographical Revenue

Figure 23 ALLERGAN: Key Financials

Figure 24 ALLERGAN: Segmental Revenue

Figure 25 ALLERGAN: Geographical Revenue

Figure 26 Bayer AG: Key Financials

Figure 27 Bayer AG: Segmental Revenue

Figure 28 Bayer AG: Geographical Revenue

Figure 29 Astellas Pharma, Inc: Key Financials

Figure 30 Astellas Pharma, Inc: Segmental Revenue

Figure 31 Astellas Pharma, Inc: Geographical Revenue

Figure 32 GlaxoSmithKline plc: Key Financials

Figure 33 GlaxoSmithKline plc: Segmental Revenue

Figure 34 GlaxoSmithKline plc: Geographical Revenue